Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Filgotinib - Lakefront Biotherapeutics/Gilead Sciences

Next Previous
Drug Profile

Filgotinib - Lakefront Biotherapeutics/Gilead Sciences

Alternative Names: Filgotinib hydrochloride; Filgotinib Maleate; G-146034; G-146034-101; GLPG-0634; GS-6034; Jyseleca

Latest Information Update: 31 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galapagos NV
  • Developer Alfasigma; Eisai Co Ltd; Galapagos NV; Gilead Sciences; Lakefront Biotherapeutics
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Cyclopropanes; Pyridines; Skin disorder therapies; Small molecules; Thiamorpholines; Triazoles; Urologics
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis; Ulcerative colitis
  • Phase III Axial spondyloarthritis; Juvenile rheumatoid arthritis
  • Discontinued Ankylosing spondylitis; Crohn's disease; Cutaneous lupus erythematosus; Lupus nephritis; Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Sjogren's syndrome; Uveitis

Most Recent Events

  • 15 Jul 2026 Alfasigma terminates a phase-I trial in Juvenile rheumatoid arthritis (In children, In adolescents, Treatment-experienced) in France, Germany, United Kingdom, Poland and Spain (PO) due to sponsor decision to stop recruitment(NCT06222034) (EudraCT2023-505844-21-00)
  • 06 Jun 2026 Efficacy data from the phase III OLINGUITO trial in Axial spondyloarthritis presented at the 27th Annual Congress of the European League Against Rheumatism (EULAR-2026)
  • 21 May 2026 Phase-III clinical trials in Juvenile rheumatoid arthritis (In adolescents, In children, Treatment-experienced) in Belarus, Czech Republic, Hungary, Italy, Poland, Spain, United Kingdom, Germany, France (PO) (NCT07554495)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top